07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Peptech other research news

PTD received a two-year grant of up to AUS$2.3 million (US$1.8 million) from the Australian government's new START program, which supports industry R&D projects aimed at bringing new products and technologies to the market place....
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Peptech, Medical Research Council deal

The parties will develop approaches to the generation of peptide libraries for use in drug screening. PTD will fund ongoing research at the Council, and the company will develop peptide-based drugs using the technology. PTD...
08:00 , Feb 27, 2006 |  BC Week In Review  |  Company News

Biosignal Ltd., Australian Surgical Design & Manufacture Pty Ltd, Institute for Eye Research deal

The parties partnered to develop catheters and orthopedic implants that are coated with antibacterial compounds from BOS. The institute will invest AUS$430,000 (US$318,000) in the project, while orthopedics company Australian Surgical will invest AUS$590,000 (US$436,000)....
07:00 , Apr 18, 2005 |  BioCentury  |  Finance

Ebb & Flow

As the sign says, "objects in the rear view mirror are closer than they appear." On the heels of last week's positive Phase III data for Avastin as first-line therapy for metastatic breast cancer, and...
07:00 , Apr 11, 2005 |  BC Week In Review  |  Company News

Absalus Inc., EvoGenix Pty Ltd. deal

EvoGenix is acquiring cancer antibody company, Absalus, for AUS$8 million (US$6.2 million) in stock. The companies have a 2004 deal to develop therapeutic antibodies. EvoGenix develops protein therapeutic discovery and optimization technology. Absalus Inc. ,...
08:00 , Mar 14, 2005 |  BC Week In Review  |  Company News

Metabolic, Neuren deal

The companies partnered to co-develop NEU's neuro-regenerative peptides (NRPs). The neuronal growth factors are in preclinical development for degenerative diseases. The partners hope to identify a lead candidate over the next 18 months. MBP will...
08:00 , Mar 14, 2005 |  BioCentury  |  Finance

Ebb & Flow

TransForm Pharmaceuticals is the third MPM portfolio company in the past few weeks to be taken out by a large pharma company. The exits could help make MPM's limited partners happy, as the firm gears...
08:00 , Feb 28, 2005 |  BC Week In Review  |  Company News

ChemGenex Pharmaceuticals Inc., Vernalis deal

CXS received a AUS$720,000 (US$568,000) milestone payment from VER under their 2004 depression target discovery deal (see BioCentury, Sept. 20, 2004). The companies did not disclose what triggered the milestone. ChemGenex Pharmaceuticals Inc. (ASX:CXS), Melbourne,...
08:00 , Jan 24, 2005 |  BC Week In Review  |  Company News

Avexa, Shire Pharmaceuticals Group plc deal

SHP granted AVX a license to SPD754, a cytidine analog nucleoside reverse transcriptase inhibitor (NRTI) to treat HIV. SPD754 has completed Phase IIa trials. Avexa is responsible for global development of SPD754 and has global...
08:00 , Jan 18, 2005 |  BC Extra  |  Company News

Avexa in-licenses Shire HIV compound

Shire (LSE:SHP; SHPGY) granted Avexa (ASX:AVX) a license to SPD754 cytidine analog nucleoside reverse transcriptase inhibitor (NRTI) to treat HIV. SPD754 has completed Phase IIa trials. Avexa is responsible for global development of SPD754 and...